ESI has been in the forefront of developing hES cell technology since its inception in 2000.
ESI’s propriety technologies cover:
ESI generated 6 clinical-grade human embryonic stem cell lines (Crook et al, 2007). These cell lines are the first to have been produced following the principles of Good Manufacturing Practice. These cell lines are available from ESI to interested parties under a variety of terms and conditions.
Derivation of hESC-derived Cardiomyocytes
ESI has developed various culture conditions for inducing differentiation of stem cells to cardiomyocytes. The methods yield a high percentage of cardiomyocytes in either suspension or adherent cultures suitable to a number of applications including drug testing and cardiotoxicity assays (Graichen et al 2007; Xu et al 2008).
ESI has captured early Intellectual Property regarding the derivation of neural progenitor cells from hESCs (Reubinoff et al 2001). This technology is under development with our subsidiary, CellCure NeuroSciences Ltd.
Technology and IP for Diabetes Research
ESI holds a number of patents relating to early endoderm differentiation and adult pancreatic progenitor cell populations. We have also developed methods of differentiating hESC towards insulin producing cells (Philips et al 2007).